In clinic US guided entheseal biopsy? Abs 1025 at #ACR22 recommends the lateral epicondyle tendon plate in PsA pts. @RheumNow https://t.co/VomyFkecLq

• Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Enthese…

Window of opportunity in PsA CorEvitas registry: Early initiators had more severe disease & worse PROs but if DMARD therapy initiated within 1 yr: RR=2 MDA achievement & higher reduction of CDAI https://t.co/Xm9i7aiq85 Abs#1493 #ACR22 @Rheumnow https://t.co/RAGoHeuSIg

• Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs…

Performance BASDAI & ASDAS in evaluating PsA axial symptoms? 400+ pts DISCOVER 1&2 Weak correlations w/ peripheral arthritis Moderate/strong correlations w/ fatigue & pain Both perform similarly but do they perform well enough? https://t.co/alnrEXtydp Abs#1037 #ACR22 @Rheumnow https://t.co/Zuf1FruneK

• Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients wit…

Low likelihood of syndesmophyte formation in PsA but is more likely assoc'd w/ axial involvement radiographically + high CRP. Abs 1014 #ACR22 @RheumNow https://t.co/M5Tc0fd64s https://t.co/e25gwVQKeo

• Is Radiographic Axial Involvement Associated with Syndesmophyte Development Aft…

DISCOVER 1 & 2: Subanalysis of GUS in 181 pts w/ Axial PsA and imaging confirmed SI GUS improves BASDAI, mBASDAI, spinal pain, morning stiffness, and ASDAS from W8 to W24 W24 Response rates BASDAI50 38% BASDAI70 20% https://t.co/MrS8atrIOI Abs#1035 #ACR22 @Rheumnow https://t.co/wMDkO1Qak9

• Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axi…

Abstr #1037 evaluated BASDAI vs ASDAS in PsA w/ axial dx Both ASDAS & BASDAI showed - strong correlation w/ pt pain & Global Assessment - weak correlation in tender and swollen joint counts and enthesitis #ACR22 @RheumNow #axSpA #PsA https://t.co/EunXIwzn3M

Valero et al. Combined biologics in PsA. @RheumNow #ACR22 Abstr1044 https://t.co/7nNf0Ktf0M https://t.co/CIE9BnBFvx

• Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a…

Can we predict PsA incidence and prevalence trends? Germany long-term projection 2040 3 scenarios: 1. increase 5%/yr 2. stable 3. decrease 5%/yr. Best scenario (3) = peak diagnoses in 2028. Are medical resources ready for it? https://t.co/ws87zDukuM Abs#1019 #ACR22 @Rheumnow https://t.co/dqkfrag0w2

• Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Proje…

Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0

• A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics an…

#abst1012 #acr22 @rheumnow CASIPSA Study of SI CT in 48 PsA pts vs 48 controls. Disease duration 22.87 ± 14.95 y, 43.48 %HLA-B27+. higher prevalences of erosion in PsA (18%) preferentially located on the anterior and middle regions of the SIJs https://t.co/4dtJNCKf4I

axPsA and AS adult pts exhibit different genetic risk factors & serum IL-17 levels. GUS demonstrated significant pharmacodynamic effects and clinical improvement in axPsA and non-axPsA pts. Abs 1038 #ACR22 @RheumNow https://t.co/9Rjw7usO8J

• Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylo…

JAK and TYK-2 inhibitors and indications in SpA: ● Tofacitinib ➣ Pan JAKi (AS, PsA) ● Baricitinib ➣ JAK1,2 ● Upadacitinib ➣ JAK1 (AxSpA, PsA) ● Deucravacitinib ➣ TYK2 (PsA) Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS

Differences between #uveitis pattern in AS vs. PsA and IBD 👇 This is always asked to our rheum fellows during Kelley's hour 🤓 #ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06